Precigen vs UroGen Pharma
PGEN and URGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PGEN and URGN compare
Precigen and UroGen Pharma are about the same size, with market caps of $1.5B and $1.5B.
UroGen Pharma scores higher on the StockData Score (6 against 2 for Precigen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PGEN | URGN |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $1.5B |
| Share price | $4.29 | $29.87 |
| Change, 1 year | −11.5% | 25.7% |
| Change, 5 years | 11.1% | 146% |
| Beta (5Y) | 1.20 | 2.73 |
| Employees | 20 | 291 |
| StockData Score | ||
| Total score | 2 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 3 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 7.7× |
| P/B | 35.2× | – |
| FCF yield | −7.5% (better) | −10.9% |
| Growth | ||
| Revenue growth (TTM) | – | 100% |
| Revenue growth, 5Y average | −21.3% | 56.2% (better) |
| Profitability | ||
| Gross margin | – | 90.8% |
| Operating margin | – | −35.3% |
| Net margin | – | −51.7% |
| FCF margin | – | −84.3% |
| Return on equity | −4640% | – |
| Financial health | ||
| Debt / equity | 2.15 | – |
| Current ratio | 4.58 (better) | 3.80 |
| Altman Z-score | −11.14 | −2.55 (better) |
| Piotroski F-score | 2 (better) | 0 |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 39.2% | 86.8% |
| Held by insiders | 44.9% | 5.6% |
| Insider net buying, 12 months | −$32.5M | −$4.5M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 22.8% | 11.1% |
Go deeper
- PGEN stock overview
- PGEN income statement
- PGEN valuation and score
- URGN stock overview
- URGN income statement
- URGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.